Use of the Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1) in the Diagnosis of Pleural Effusion
Status
Conditions
Details and patient eligibility
About
The aim of this trial is to evaluate the level of TREM-1 in different kinds of pleural effusion.
Full description
The triggering receptor expressed on myeloid cells-1 (TREM-1) is a member of the immunoglobulin superfamily, and its expression is upregulated on phagocytic cells in the presence of bacteria or fungi. Several experiments by Bouchon and colleagues showed that TREM-1 mediates the acute inflammatory response to microbial products. Human tissues infected with bacteria are infiltrated with neutrophils and macrophages that express high levels of TREM-1. Conversely, TREM-1 is only weakly expressed in samples from patients with noninfectious inflammatory disorders. In addition, TREM-1 is shed from the membrane of activated phagocytes and can be found in a soluble form in body fluids. The presence of a soluble form of TREM-1 in samples of bronchoalveolar lavage fluid from mechanically ventilated patients has been shown to be a good indicator of infectious pneumonia.
Sex
Ages
Volunteers
Inclusion criteria
- Clinical diagnosis of pleural effusion
- Pleural effusion proved by chest sonography
Exclusion criteria
- Conditions for which thoracentesis are contraindicated
- Pregnancy
Trial contacts and locations
Loading...
Central trial contact
Pan-Chyr Yang, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal